Gunilla Ekstrom - Karolinska Development Vice President - Operations
| KDEV Stock | SEK 1.55 0.02 1.31% |
President
Dr. Gunilla Ekstrom was Vice President Operations at Karolinska Development AB since June 2012. Gunilla Ekstrom has over 20 years of experience from senior positions in the pharmaceutical industry including as Senior Vice President at Orexo AB and Global Product Director at AstraZeneca RD. She is also Board member of Athera Biotechnologies AB Biosergen AS Inhalation Sciences Sweden AB Lipidor AB NovaSAID AB Pharmanest AB and CEO of Biosergen AS. She holds Doctorate of Medicine and Doctorate in Philosophy degrees and is Associate Professor at Karolinska Institutet. since 2012.
| Age | 54 |
| Tenure | 12 years |
| Professional Marks | Ph.D |
| Phone | 46 8 52 48 60 70 |
| Web | https://www.karolinskadevelopment.com |
Karolinska Development Management Efficiency
The company has return on total asset (ROA) of (0.0168) % which means that it has lost $0.0168 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.1059) %, meaning that it generated substantial loss on money invested by shareholders. Karolinska Development's management efficiency ratios could be used to measure how well Karolinska Development manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 5 records | PRESIDENT Age | ||
| Johannes Doll | Orexo AB | 37 | |
| Cecilia Coupland | Orexo AB | 47 | |
| Robert DeLuca | Orexo AB | 62 | |
| Robert Ronn | Orexo AB | 47 | |
| Yong Kang | Anoto Group AB | N/A | |
Management Performance
| Return On Equity | -0.11 | |||
| Return On Asset | -0.0168 |
Karolinska Development Leadership Team
Elected by the shareholders, the Karolinska Development's board of directors comprises two types of representatives: Karolinska Development inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Karolinska. The board's role is to monitor Karolinska Development's management team and ensure that shareholders' interests are well served. Karolinska Development's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Karolinska Development's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Hans Wigzell, Independent Chairman of the Board | ||
| Elisabet Gimbringer, Controller | ||
| Carl Sundberg, Director | ||
| Magnus Persson, Director | ||
| Jim Heusden, CEO | ||
| Maria Ferm, Executive Assistant | ||
| HansOlov Olsson, Director | ||
| Theresa Tse, Director | ||
| Viktor Drvota, Chief Investment Officer | ||
| Esther Simo, Analyst | ||
| John MD, Chief Partner | ||
| Eva Montgomerie, Head of Accounting | ||
| Michael Owens, Controller | ||
| Yan Cheng, President Asia | ||
| Ulf Richenberg, General Counsel | ||
| Niclas Adler, Director | ||
| Tse Ping, Director | ||
| Christian Tange, CFO | ||
| Daniel Bolanowski, Business Analyst | ||
| Per Aniansson, Investment Director | ||
| Johan Dighed, Chief CEO | ||
| Terje Kalland, Chief Scientific Officer | ||
| Linda Spahiu, Investment Mang | ||
| Vladimir Artamonov, Independent Director | ||
| Felicia Rittemar, Analyst | ||
| AnnSofie Sternas, Vice President IPR | ||
| Anders Harfstrand, Director | ||
| Bo Hansen, Chairman of the Board | ||
| Viktor MD, Chief Officer | ||
| Fredrik Jarrsten, CFO | ||
| Khalid Islam, Director | ||
| Gunilla Ekstrom, Vice President - Operations | ||
| Hans Toll, Chief Officer | ||
| Henrijette Richter, Director |
Karolinska Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Karolinska Development a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.11 | |||
| Return On Asset | -0.0168 | |||
| Operating Margin | (14.44) % | |||
| Current Valuation | 247.24 M | |||
| Shares Outstanding | 267.28 M | |||
| Shares Owned By Insiders | 37.17 % | |||
| Shares Owned By Institutions | 5.97 % | |||
| Price To Earning | 7.42 X | |||
| Price To Book | 0.37 X | |||
| Price To Sales | 204.26 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Karolinska Development AB. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Complementary Tools for Karolinska Stock analysis
When running Karolinska Development's price analysis, check to measure Karolinska Development's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Karolinska Development is operating at the current time. Most of Karolinska Development's value examination focuses on studying past and present price action to predict the probability of Karolinska Development's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Karolinska Development's price. Additionally, you may evaluate how the addition of Karolinska Development to your portfolios can decrease your overall portfolio volatility.
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |